Bio

Ashley Friedman has over 20 years of healthcare investing and finance experience. Throughout his career, he has focused on the pharmaceutical and medical devices sectors. Ashley joined Signet Healthcare Partners in 2014 and focuses on pharmaceutical, medical devices and diagnostics investments. Ashley currently serves on the Board of Directors of Altasciences and Smart Medical Systems and is a Board Observer at Pharmaceutics International (Pii). Ashley was previously a Board member at GI Supply (acquired by Laborie Medical Technologies), TELA Bio (NSDQ: TELA), and Vigene Biosciences (acquired by Charles River Laboratories). Prior to joining Signet, Ashley spent over 11 years, most recently as a Vice President, working for Investor Growth Capital (Investor AB), a venture capital firm focusing on private and public healthcare investments. While at Investor Growth Capital, Ashley was involved with several successful investments in the biotechnology, specialty pharmaceutical and medical devices sectors. Prior portfolio companies include Achillion Pharmaceuticals (NSDQ: ACHN), Cayenne Medical (acquired by Zimmer Biomet), CHF Solutions (acquired by Gambro), Corcept Therapeutics (NSDQ: CORT) and LifeCell Corporation (part of Abbvie). Ashley began his career at Lehman Brothers as a healthcare investment banker. Ashley holds a Bachelor of Science from Yale University in both Economics and Molecular, Cellular & Developmental Biology (MCDB) with a concentration in biotechnology.